vTv Therapeutics Inc VTVT

NAS: VTVT | ISIN: US9183851057   26/04/2024
26,97 USD (+4,64%)
(+4,64%)   26/04/2024

19 maart 2024 · Cantex Pharmaceuticals To Present At 5Th Annual Glioblastoma Drug Development Summit · Persbericht

22 februari 2024 · CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE · Persbericht

27 september 2023 · Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Pivotal Clinical Trial To Evaluate The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For Covid-19 · Persbericht

26 september 2023 · Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer · Persbericht

18 september 2023 · Cantex Pharmaceuticals And Lenox Hill Hospital Announce Initiation Of A Phase 2 Study Of Rage Inhibitor Azeliragon As A Front-Line Treatment For Unmethylated Glioblastoma · Persbericht

10 augustus 2023 · Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer · Persbericht

15 juni 2023 · Cantex Pharmaceuticals To Present At The Medinvest Oncology Investor Conference In Boston · Persbericht

20 april 2023 · Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 · Persbericht

6 maart 2023 · Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases · Persbericht

27 februari 2023 · Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma · Persbericht

9 januari 2023 · Cantex Pharmaceuticals Receives Fda Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma · Persbericht

30 maart 2022 · vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update · Persbericht

4 maart 2022 · vTv Therapeutics Announces CEO Transition · Persbericht

20 oktober 2021 · vTv Therapeutics Announces Deepa Prasad as New President and CEO · Persbericht

18 maart 2021 · vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes · Persbericht

8 maart 2021 · vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference · Persbericht

24 februari 2021 · vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update · Persbericht

23 februari 2021 · vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes · Persbericht

17 februari 2021 · vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis · Persbericht

6 januari 2021 · vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually · Persbericht

Mijn selecties